Loading...
•
Jun 30, 2023
Acelyrin Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023 and highlighted additional recent corporate updates and milestones.
Key Takeaways
ACELYRIN reported its Q2 2023 financial results, highlighting clinical and corporate milestones, including new data from the Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa and the completion of enrollment in the Phase 2b/3 trial of izokibep in Psoriatic Arthritis. The company's strong cash position of $823.0 million, including gross proceeds from a recent IPO of $621.0 million, is expected to support multiple late-stage clinical programs.
New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4.
Enrollment completed in Phase 2b/3 randomized controlled trial of izokibep in Psoriatic Arthritis; top-line data now accelerated to first quarter 2024 from mid-2024.
Strong cash position of $823.0 million, including gross proceeds from recent IPO of $621.0 million, supports multiple late-stage clinical programs through key milestones across all three clinical programs.
Ken Lock appointed as Chief Commercial Officer.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...